Cross‐Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine
Open Access
- 1 November 2007
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 196 (9) , 1313-1320
- https://doi.org/10.1086/521304
Abstract
Background. Avian H5N1 influenza A virus is an emerging pathogen with the potential to cause substantial human morbidity and mortality. We evaluatedKeywords
This publication has 26 references indexed in Scilit:
- Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infectionMicrobes and Infection, 2006
- Isolation of drug-resistant H5N1 virusNature, 2005
- Evolution of H5N1 Avian Influenza Viruses in AsiaEmerging Infectious Diseases, 2005
- Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus InfectionJournal of Virology, 2005
- Probable Person-to-Person Transmission of Avian Influenza A (H5N1)New England Journal of Medicine, 2005
- Lethal H5N1 influenza viruses escape host anti-viral cytokine responsesNature Medicine, 2002
- Human influenza A H5N1 virus related to a highly pathogenic avian influenza virusThe Lancet, 1998
- Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory IllnessScience, 1998
- A pandemic warning?Nature, 1997
- Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.1994